# Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy

> **NCT05044039** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 42 (actual)

## Conditions studied

- Non-hodgkin Lymphoma
- Acute Lymphocytic Leukemia

## Interventions

- **DRUG:** Duvelisib

## Key facts

- **NCT ID:** NCT05044039
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-02-28
- **Primary completion:** 2026-01-06
- **Final completion:** 2030-05-22
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2026-02-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05044039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05044039, "Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT05044039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*